[go: up one dir, main page]

FR2947455B1 - La dermaseptine b2 comme inhibiteur de la croissance tumorale - Google Patents

La dermaseptine b2 comme inhibiteur de la croissance tumorale

Info

Publication number
FR2947455B1
FR2947455B1 FR0954505A FR0954505A FR2947455B1 FR 2947455 B1 FR2947455 B1 FR 2947455B1 FR 0954505 A FR0954505 A FR 0954505A FR 0954505 A FR0954505 A FR 0954505A FR 2947455 B1 FR2947455 B1 FR 2947455B1
Authority
FR
France
Prior art keywords
dermaseptin
inhibitor
tumor growth
peptides
fragments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0954505A
Other languages
English (en)
Other versions
FR2947455A1 (fr
Inventor
Jean Delbe
Mohamed Amiche
Ali Ladram
Cecile Galanth
Pierre Nicolas
Yamina Hamma
Zoggel Johanna Allegonda Anna Van
Jose Courty
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite Pierre et Marie Curie
Universite Paris Est Creteil Val de Marne
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0954505A priority Critical patent/FR2947455B1/fr
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Priority to US13/381,477 priority patent/US20120184498A1/en
Priority to PCT/FR2010/051347 priority patent/WO2011001097A1/fr
Priority to JP2012518115A priority patent/JP5898071B2/ja
Priority to EP10745672.5A priority patent/EP2448594B1/fr
Priority to CA2767012A priority patent/CA2767012C/fr
Priority to CN201080036431.3A priority patent/CN102596222B/zh
Publication of FR2947455A1 publication Critical patent/FR2947455A1/fr
Priority to IL217247A priority patent/IL217247A/en
Application granted granted Critical
Publication of FR2947455B1 publication Critical patent/FR2947455B1/fr
Priority to US14/473,855 priority patent/US20140369987A1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/463—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from amphibians
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FR0954505A 2009-07-01 2009-07-01 La dermaseptine b2 comme inhibiteur de la croissance tumorale Expired - Fee Related FR2947455B1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
FR0954505A FR2947455B1 (fr) 2009-07-01 2009-07-01 La dermaseptine b2 comme inhibiteur de la croissance tumorale
PCT/FR2010/051347 WO2011001097A1 (fr) 2009-07-01 2010-06-29 La dermaseptine b2 comme inhibiteur de la croissance tumorale
JP2012518115A JP5898071B2 (ja) 2009-07-01 2010-06-29 腫瘍成長の阻害剤としてのデルマセプチンｂ２
EP10745672.5A EP2448594B1 (fr) 2009-07-01 2010-06-29 La dermaseptine b2 comme inhibiteur de la croissance tumorale
US13/381,477 US20120184498A1 (en) 2009-07-01 2010-06-29 Dermaseptin b2 used as an inhibitor of the growth of a tumor
CA2767012A CA2767012C (fr) 2009-07-01 2010-06-29 La dermaseptine b2 comme inhibiteur de la croissance tumorale
CN201080036431.3A CN102596222B (zh) 2009-07-01 2010-06-29 作为肿瘤生长的抑制剂的皮抑菌肽b2
IL217247A IL217247A (en) 2009-07-01 2011-12-28 Isolated peptides, chimeric molecules and pharmaceuticals containing them, methods for their preparation, encoded nucleic acids, vectors containing the nucleic acids, for use in growth inhibition or cell proliferation to treat proliferative syndromes, ocular lesions and autoimmune diseases
US14/473,855 US20140369987A1 (en) 2009-07-01 2014-08-29 Dermaseptin b2 used as an inhibitor of the growth of a tumor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0954505A FR2947455B1 (fr) 2009-07-01 2009-07-01 La dermaseptine b2 comme inhibiteur de la croissance tumorale

Publications (2)

Publication Number Publication Date
FR2947455A1 FR2947455A1 (fr) 2011-01-07
FR2947455B1 true FR2947455B1 (fr) 2014-01-03

Family

ID=41650244

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0954505A Expired - Fee Related FR2947455B1 (fr) 2009-07-01 2009-07-01 La dermaseptine b2 comme inhibiteur de la croissance tumorale

Country Status (8)

Country Link
US (2) US20120184498A1 (fr)
EP (1) EP2448594B1 (fr)
JP (1) JP5898071B2 (fr)
CN (1) CN102596222B (fr)
CA (1) CA2767012C (fr)
FR (1) FR2947455B1 (fr)
IL (1) IL217247A (fr)
WO (1) WO2011001097A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3061178B1 (fr) * 2016-12-22 2021-02-12 Univ Pierre Et Marie Curie Paris 6 Upmc Peptides antimicrobiens et leurs utilisations
AU2018321825A1 (en) * 2017-08-19 2020-03-05 Ohio State Innovation Foundation Novel peptide-based cancer imaging agents

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5433955A (en) 1989-01-23 1995-07-18 Akzo N.V. Site specific in vivo activation of therapeutic drugs
CA2357538A1 (fr) 1989-03-21 1990-10-04 Wisconsin Alumni Research Foundation Expression des sequences pollynocleotides exogenes chez un vertebre
EP0753069A1 (fr) * 1994-04-15 1997-01-15 Targeted Genetics Corporation Proteine de fusion d'apport de gene
FR2735983B1 (fr) * 1995-06-29 1997-12-05 Centre Nat Rech Scient Peptide permettant de modifier l'activite du systeme immunitaire humain ou animal
US20020150964A1 (en) * 1995-12-19 2002-10-17 Centre National De La Recherche Scientifique Peptides for the activation of the immune system in humans and animals
US5760072A (en) 1995-12-29 1998-06-02 Pharmachemie B.V. Paclitaxel prodrugs, method for preparation as well as their use in selective chemotherapy
CA2174803C (fr) * 1996-04-23 2000-07-11 Jonathan P. Wong Utilisation de ciprofloxacine encapsulee dans un liposome comme medicament immunotherapeutique
CN1168740C (zh) * 2001-04-04 2004-09-29 上海美恩生物技术有限公司 细胞因子基因修饰的抗原提呈细胞/肿瘤细胞偶联物、其制法和用途
US20070207209A1 (en) * 2004-08-27 2007-09-06 Murphy Christopher J Trophic factor combinations for nervous system treatment
FR2900341B1 (fr) 2006-04-27 2012-09-14 Centre Nat Rech Scient Utilisation de ligands synthetiques multivalents de la nucleoline de surface pour le traitement du cancer

Also Published As

Publication number Publication date
FR2947455A1 (fr) 2011-01-07
IL217247A (en) 2016-02-29
CN102596222A (zh) 2012-07-18
US20140369987A1 (en) 2014-12-18
EP2448594A1 (fr) 2012-05-09
IL217247A0 (en) 2012-02-29
EP2448594B1 (fr) 2018-02-28
WO2011001097A1 (fr) 2011-01-06
US20120184498A1 (en) 2012-07-19
JP2012531218A (ja) 2012-12-10
JP5898071B2 (ja) 2016-04-06
CA2767012A1 (fr) 2011-01-06
CA2767012C (fr) 2018-10-16
CN102596222B (zh) 2014-11-26

Similar Documents

Publication Publication Date Title
IN2012DN03883A (fr)
NZ754051A (en) Novel antibodies and uses thereof
EA200900819A1 (ru) Хиназолины для ингибирования pdk1
WO2010011296A3 (fr) Inhibiteurs de désacétylase et leurs utilisations
CA2871471C (fr) Inhibiteurs d'adn pk
EA200870415A1 (ru) Хиназолины для ингибирования pdk 1
MX2013004726A (es) Anticuerpos dkk1 y metodos de uso.
EA201101650A1 (ru) Новые производные пиримидина и их применение в лечении злокачественных новообразований и последующих заболеваний
MY153766A (en) Derivatised proline containing peptide organic compounds as protease inhibitors
UA107783C2 (en) Isoindoline compounds for use in treating cancer
EA201291143A1 (ru) Пиразолилхиназолиновые ингибиторы киназы
UY33334A (es) Proteina de fusion Robol-Fc y su utilizacion en el tratamiento de tumores .
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
EA201200473A1 (ru) Замещенные (гетероарилметил)тиогидантоины
MX2010005651A (es) Inhibicion de receptor de proteina de estimulacion de macrofagos (ron) y sus metodos de tratamiento.
EA201070247A1 (ru) Ингибиторы протеасом
EA201390772A1 (ru) Новые соли и полиморфные формы афатиниба
WO2010048026A3 (fr) Inhibiteurs de récepteur de facteur de croissance des fibroblastes 3 (fgfr-3) et procédés de traitement
AU2011338389A8 (en) Bicyclic compounds as Pim inhibitors
WO2010014253A3 (fr) Composés inhibiteurs d’ant4 et leurs procédés d’utilisation
MX2011011768A (es) Composiciones y metodos de uso para moleculas de enlace a dickkopf-1 o dickkopf-4 o a ambos.
MX2009012271A (es) Compuestos antagonistas de acido ribonucleico para la modulacion de her3.
EP3747457A3 (fr) Protéine du facteur 1, protéine du facteur 2 et leurs inhibiteurs destinés à être utilisés dans le traitement ou la prévention de maladies
MX2012015100A (es) Compuestos y composiciones de heteroarilo como inhibidores de cinasa de proteina.
WO2007125331A3 (fr) Amino-éthyl-amino-aryles (aeaa) et leurs applications

Legal Events

Date Code Title Description
AU Other action affecting the ownership or exploitation of an industrial property right

Effective date: 20130711

TQ Partial transmission of property

Owner name: L'UNIVERSITE PIERRE ET MARIE CURIE, FR

Effective date: 20130711

Owner name: UNIVERSITE PARIS EST CRETEIL VAL DE MARNE, FR

Effective date: 20130711

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (, FR

Effective date: 20130711

PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11

ST Notification of lapse

Effective date: 20210305